Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

au pharma pty ltd - buprenorphine, quantity: 10 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; levulinic acid; oleyl oleate; povidone; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; glycidyl methacrylate; 2-hydroxyethyl acrylate - b-patch patches are indicated for the management of severe pain where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment.,b-patch patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. b-patch patches are not indicated as an as-needed (prn) analgesia.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

au pharma pty ltd - buprenorphine, quantity: 20 mg - drug delivery system, transdermal - excipient ingredients: oleyl oleate; povidone; polyethylene terephthalate; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; glycidyl methacrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate; butyl acrylate; acrylic acid; aluminium acetylacetonate; heptane - b-patch patches are indicated for the management of severe pain where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment.,b-patch patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. b-patch patches are not indicated as an as-needed (prn) analgesia.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

natus medical pty ltd - 47714 - subdermal needle electrode - sterile subdermal needle electrode for use with the electro neuro diagnostic system

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

rowex ltd - fentanyl - transdermal patch - 100 microgram

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

rowex ltd - fentanyl - transdermal patch - 25 microgram

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

rowex ltd - fentanyl - transdermal patch - 50 microgram

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

rowex ltd - fentanyl - transdermal patch - 75 microgram

Ισραήλ - Αγγλικά - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

Ισραήλ - Αγγλικά - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

Ισραήλ - Αγγλικά - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.